J&J professes ‘voracious’ appetite for medtech M&A following Abiomed megadeal

After reshaping itself as a two-sector company with the spinout of its consumer health division this year, Johnson & Johnson posted ongoing gains across its medtech segments—and said it has a “pretty voracious” appetite for device M&A going forward, while it expects rebounds in surgery volume to continue funneling cash into the coffers for the rest of the year.

error: Content is protected !!